Prognostic utility of pulse pressure in patients with heart failure with preserved ejection fraction: The RICA Registry.

Arterial stiffness Fracción de eyección del ventrículo izquierdo Heart failure Left ventricular ejection fraction Mortalidad Mortality Presión de pulso Pulse pressure Rigidez arterial insuficiencia cardiac

Journal

Revista clinica espanola
ISSN: 2254-8874
Titre abrégé: Rev Clin Esp (Barc)
Pays: Spain
ID NLM: 101632437

Informations de publication

Date de publication:
04 2023
Historique:
received: 22 11 2022
accepted: 31 01 2023
medline: 11 4 2023
pubmed: 20 3 2023
entrez: 19 3 2023
Statut: ppublish

Résumé

The prognostic role of pulse pressure (PP) in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF) is not well understood. Our aim was to evaluate it in acute and stable HF. This work is a retrospective observational study of patients included in the RICA registry between 2008 and 2021. Blood pressure was collected on admission (decompensation) and 3 months later on an outpatient basis (stability). Patients were categorized according to whether the PP was greater or less than 50mmHg. All-cause mortality was assessed at 1year after admission. A total of 2291 patients were included, with mean age 80.1±7.7 years. 62.9% were women and 16.7% had a history of coronary heart disease. In the acute phase, there was no difference in mortality according to PP values, but in the stable phase PP<50mmHg was independently associated with all-cause mortality at 1-year follow-up (HR 1.57, 95% CI 1.21-2.05, p=0.001), after adjusting for age, sex, New York Heart Association functional class, previous HF, chronic kidney disease, valvular heart disease, cerebrovascular disease, score on the Barthel and Pfeiffer scales, hemoglobin and sodium levels. Low stable-phase PP was associated with increased all-cause mortality in HF patients with preserved LVEF. However, PP was not useful as a prognostic marker of mortality in acute HF. Further studies are needed to assess the relationship of this variable with mortality in HF patients.

Sections du résumé

BACKGROUND AND AIMS
The prognostic role of pulse pressure (PP) in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF) is not well understood. Our aim was to evaluate it in acute and stable HF.
MATERIAL AND METHODS
This work is a retrospective observational study of patients included in the RICA registry between 2008 and 2021. Blood pressure was collected on admission (decompensation) and 3 months later on an outpatient basis (stability). Patients were categorized according to whether the PP was greater or less than 50mmHg. All-cause mortality was assessed at 1year after admission.
RESULTS
A total of 2291 patients were included, with mean age 80.1±7.7 years. 62.9% were women and 16.7% had a history of coronary heart disease. In the acute phase, there was no difference in mortality according to PP values, but in the stable phase PP<50mmHg was independently associated with all-cause mortality at 1-year follow-up (HR 1.57, 95% CI 1.21-2.05, p=0.001), after adjusting for age, sex, New York Heart Association functional class, previous HF, chronic kidney disease, valvular heart disease, cerebrovascular disease, score on the Barthel and Pfeiffer scales, hemoglobin and sodium levels.
CONCLUSIONS
Low stable-phase PP was associated with increased all-cause mortality in HF patients with preserved LVEF. However, PP was not useful as a prognostic marker of mortality in acute HF. Further studies are needed to assess the relationship of this variable with mortality in HF patients.

Identifiants

pubmed: 36934810
pii: S2254-8874(23)00040-1
doi: 10.1016/j.rceng.2023.01.006
pii:
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-239

Informations de copyright

Copyright © 2023. Published by Elsevier España, S.L.U.

Auteurs

I Bravo Candela (I)

Medicina Interna, Hospital Universitario Virgen Macarena, Sevilla, Spain.

N Moya González (N)

Medicina Interna, Hospital Universitario Virgen Macarena, Sevilla, Spain.

P Salamanca Bautista (P)

Medicina Interna, Hospital Universitario Virgen Macarena, Sevilla, Spain; Universidad de Sevilla, Sevilla, Spain. Electronic address: msalamanca2@us.es.

J Pérez Silvestre (J)

Medicina Interna, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.

A Conde Martel (A)

Medicina Interna, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.

S Carrascosa García (S)

Medicina Interna, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.

M Sánchez Marteles (M)

Medicina Interna, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

J M Cerqueiro González (JM)

Medicina Interna, Hospital Universitario Lucus Augusti, Lugo, Spain.

J Casado Cerrada (J)

Medicina Interna, Hospital Universitario de Getafe, Madrid, Spain.

M Montero-Pérez-Barquero (M)

Medicina Interna, IMIBIC/Hospital Universitario Reina Sofía, Córdoba, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH